Gene
PDGFRA
PDGFRA is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (44), Actionable biomarkers (22), and 8 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
3 more sections with rows · 1 section measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention PDGFRA. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 9 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 4 of 8,875 | 0.05% | not measured | |
| 2024 | 5 of 8,597 | 0.06% | not measured | |
| 2023 | 5 of 8,275 | 0.06% | 37 of 11,460 | 0.32% |
| 2022 | 10 of 8,285 | 0.12% | 53 of 13,598 | 0.39% |
| 2021 | 7 of 8,692 | 0.08% | 65 of 15,045 | 0.43% |
| 2020 | 7 of 7,640 | 0.09% | 48 of 14,459 | 0.33% |
| 2019 | 4 of 7,300 | 0.05% | 41 of 12,159 | 0.34% |
| 2018 | 3 of 6,927 | 0.04% | 49 of 11,854 | 0.41% |
| 2017 | 8 of 6,558 | 0.12% | 45 of 11,595 | 0.39% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| therascreen PDGFRA RGQ PCR Kit | PDGFRA | QIAGEN GmbH | Gastrointestinal Stromal Tumors (GIST) | 2023-06-29 |
Assay-provider ledger (44)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| NanoString | Unclassified | Clinical validation | 1 | December 01, 2021 |
| Promega | Reagent supplier | Analytical validation | 1 | November 08, 2021 |
| Thermo Fisher | Reagent supplier | Analytical validation | 1 | November 08, 2021 |
| Agilent | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | July 01, 2021 |
| Illumina | Unclassified | Analytical validation | 2 | July 01, 2021 |
Showing 5 of 44 assay-provider companies.
Actionable biomarkers (22)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| PDGFRA-FIP1L1 fusion | Imatinib | response-associated | Chronic Eosinophilic Leukemia, Not Otherwise Specified | Cancer Genome Interpreter |
| PDGFRA-FIP1L1 fusion | Imatinib | response-associated | Hypereosinophilic syndrome | Cancer Genome Interpreter |
| PDGFRA (T674I) | Imatinib | responsive | Hypereosinophilic syndrome | Cancer Genome Interpreter |
| PDGFRA fusion | Imatinib | response-associated | Myelodysplastic/Myeloproliferative Neoplasm | Cancer Genome Interpreter |
| PDGFRA (V658A,P577S,R841K,H845Y,G853D) | Crenolanib | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
Showing 5 of 22 actionable-biomarker assertions.
Trial mentions (103)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03092128 | Trial biospecimen (AACT) |
| NCT03424876 | Trial biospecimen (AACT) |
| NCT00132015 | Trial eligibility (AACT) |
| NCT02576080 | Trial eligibility (AACT) |
| NCT02193152 | Trial eligibility (AACT) |
Showing 5 of 103 trial mentions.
Target-disease associations (958)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 15q11.2 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 46,XX disorder of sex development - anorectal anomalies | cancer or benign tumor | Mouse knockout (IMPC) |
| 46,xx sex reversal 5 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 8p23.1 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
Showing 5 of 958 associations.
Vendor sourcing (441)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Missense variant. Missense changes are a common disease-causing mec... | View ClinVar record SCV007609523.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The PDGFRA c.1495G>T; p.Val499Leu variant (rs746574289), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID... | View ClinVar record SCV004564249.2 |
| AVEO Oncology (United States) | Trial collaborator | Mentioned in trial textTrial free-text mention | PDGF-R-alpha | View trial NCT01782313 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein functio... | View ClinVar record SCV001169794.4 |
| American Society of Clinical Oncology | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Active life-threatening complication(s) from underlying eosinophilic disease (i.e., leukostasis; acute thromboembolic disease including central nervous ... | View trial NCT03801434 |
Showing 5 of 441 sourcing records.
Trial-cited literature (604)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial. | The Lancet. Oncology | 2026 | 5 |
| Long-Term Efficacy and Safety of Benralizumab Treatment for PDGFRA-Negative Hypereosinophilic Syndrome. | The journal of allergy and clinical immunology. In practice | 2025 | 8 |
| Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort. | Cancer | 2025 | 5 |
| Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial. | Cancer | 2025 | 2 |
| Phase II trial of nilotinib in PDGFR-alpha-enriched recurrent high-grade gliomas. | Neuro-oncology advances | 2025 | 1 |
Showing 5 of 604 papers.
Protein variant mentions (58)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.D1033V | 1 | 2015 | PMID 25741868 |
| p.D1071N | 1 | 2015 | PMID 25741868 |
| p.D1074E | 1 | 2015 | PMID 25741868 |
| p.D1440A | 1 | 2016 | PMID 27273432 |
| p.D154G | 1 | 2019 | PMID 30675060 |
Showing 5 of 58 variants.
Human sample screening reference (2)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.F808L | TCGA-COAD | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Complex Epithelial Neoplasms; Rectosigmoid junction; Colon | 1 | 461 | 0.22% | 0.04% to 1.22% |
| p.V536E | CCDI-MCI | Cystic, Mucinous and Serous Neoplasms; Granular Cell Tumors and Alveolar Soft Part Sarcomas; Specialized Gonadal Neoplasms; Neoplasms, NOS; Adenomas and Adenocarcinomas; Gliomas; Meningiomas; Acinar Cell Neoplasms; Odontogenic Tumors; Soft Tissue Tumors and Sarcomas, NOS; Nevi and Melanomas; Malignant Lymphomas, NOS or Diffuse; Epithelial Neoplasms, NOS; Thymic Epithelial Neoplasms; Other and unspecified parts of mouth; Rectosigmoid junction; Thyroid gland; Connective, subcutaneous and other soft tissues; Peripheral nerves and autonomic nervous system; Other endocrine glands and related structures; Retroperitoneum and peritoneum; Vagina; Other and ill-defined digestive organs; Pancreas; Renal pelvis; Bladder; Nasal cavity and middle ear; Meninges; Adrenal gland; Bones, joints and articular cartilage of limbs; Bones, joints and articular cartilage of other and unspecified sites; Breast; Skin; Thymus; Esophagus; Other and ill-defined sites in lip, oral cavity and pharynx; Larynx; Other and unspecified urinary organs; Brain; Testis; Heart, mediastinum, and pleura; Rectum; Nasopharynx; Palate; Prostate gland; Base of tongue; Accessory sinuses; Other and unspecified female genital organs; Lip; Spinal cord, cranial nerves, and other parts of central nervous system; Colon; Oropharynx; Other and ill-defined sites; Unknown; Other and ill-defined sites within respiratory system and intrathoracic organs; Other and unspecified male genital organs; Cervix uteri; Bronchus and lung; Eye and adnexa; Ovary; Small intestine; Lymph nodes; Stomach | 1 | 3,033 | 0.03% | 0.01% to 0.19% |
Literature-extracted relations (208)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| ADENOSINE TRIPHOSPHATE | Chemical | interact |
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib. | 2023 |
| Imatinib | Chemical | associate |
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. | 2022 |
| Imatinib | Chemical | negative_correlate |
A narrative review of imatinib-resistant gastrointestinal stromal tumors. | 2021 |
| Imatinib | Chemical | negative_correlate |
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. | 2021 |
| Imatinib | Chemical | negative_correlate |
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. | 2020 |
Showing 5 of 208 relation assertions.
Organizations publishing (495)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 44 | 2005 to 2024 |
| Dana-Farber Cancer Institute | Other | 42 | 2010 to 2024 |
| Government of the United States of America | Government | 36 | 2004 to 2026 |
| The University of Texas System | Academic | 29 | 2008 to 2024 |
| Mass General Brigham | Hospital | 28 | 2007 to 2024 |
Showing 5 of 495 organizations.
Where PDGFRA appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
804 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects.